Physician-Scientist Marco Davila, MD, PhD, Joins Growing Roswell Park Cellular Therapy Program
Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.
Roswell Park Neuro-Oncology Team Expands with Specially Trained Surgeon
Meet Lindsay Lipinski, MD, FAANS. Dr. Lipinski brings exertise in peripheral nerve tumors and entrapment neuropathies to the Roswell Park Neuro-Oncology Team.
Clinical Trial of Roswell Park’s SurVaxM Glioblastoma Vaccine Reveals Promising Results
Clinical Trial of Roswell Park’s SurVaxM Glioblastoma Vaccine Reveals Promising Results.
Roswell Park Presents ‘Highly Encouraging’ Phase 2A Results on SurVaxM Immunotherapy for Glioblastoma
Roswell Park Comprehensive Cancer Center Professor of Neurosurgery Michael Ciesielski, PhD, presented the most recent findings from the completed phase 2A study of the immunotherapy SurVaxM at a poster session in June at the American Society ...
Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM
Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM.